Previous HCV Non-Responders Win in Phase III Telaprevir Study

Share

Follow Us

Print this page

Vertex reports positive results from Phase III hepatitis trial

Sep 09, 2010

Vertex Pharmaceuticals, a biotechnology company, has announced that 65% of people overall achieved a sustained viral response, or SVR/viral cure, with a telaprevir-based regimen in the pivotal Phase III Realize study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

Realize was a pivotal Phase III, randomized, double-blind, placebo-controlled study conducted in 662 people at more than 100 international clinical trial sites with the majority in Europe and North America.

Continue reading this entire article:
http://www.tradingmarkets.com/news/stock-alert/vrtx_vertex-reports-positive-results-from-phase-iii-hepatitis-trial-1158872.html

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.